Immunogen
Synthesized peptide derived from human ARY2 AA range: 80-130
Specificity
This antibody detects endogenous levels of ARY2 at Human/Mouse/Rat
Source
Polyclonal, Rabbit,IgG
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Dilution rate
WB 1:500-2000
Purification process (Immunogen)
The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
Background
This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near this gene (NAT2). [provided by RefSeq, Jul 2008],
Function
catalytic activity:Acetyl-CoA + an arylamine = CoA + an N-acetylarylamine.,disease:Genetic variations in NAT2 determine N-acetylation polymorphism by a low or high NAT activity in the liver [MIM:243400]. It has been implicated in the action and toxicity of amine-containing drugs, and in the susceptibility to bladder cancer and systemic lupus erythematosus. This isozyme is responsible for this polymorphism.,function:Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.,online information:NAT alleles,online information:The Singapore human mutation and polymorphism database,similarity:Belongs to the arylamine N-acetyltransferase family.,
Fields
>>Caffeine metabolism;>>Drug metabolism - other enzymes;>>Metabolic pathways;>>Chemical carcinogenesis - DNA adducts
Human protein sequence Database
P11245
Mouse protein sequence database
P50295
Rat protein sequence database
P50298
Cellular localization
Cytoplasm.